Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06550609 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis With Inhaled Pentamidine Plus Oral Miltefosine

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 7 more changesShow less
    • Start date changed from estimate of Oct 2024 to Feb 4, 2025
    • Primary completion date: May 2027 to Nov 2027
    • Study completion date: Oct 2027 to Feb 2028
    • Eligibility criteria revised
    • Secondary endpoints: 2 to 1
    • Study description expanded, about 277 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2 study of the combination of inhaled-pentamidine plus oral miltefosine for Bolivian mucosal leishmaniasis.
Trial Details
NCT Number NCT06550609
Lead Sponsor Fundacion Nacional de Dermatologia
Conditions
(from sponsor)		 Mucosal Leishmaniasis
Related terms Leishmaniasis, Leishmaniasis, Mucocutaneous
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov